Analysis of rare fusions in NSCLC: genomic architecture and clinical implications
Objectives - Molecular diagnosis for targeted therapies has been improved significantly in non-small-cell lung cancer (NSCLC) patients in recent years. Here we report on the prevalence of rare fusions in NSCLC and dissect their genomic architecture and potential clinical implications. - Materials an...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2023
|
| In: |
Lung cancer
Year: 2023, Jahrgang: 184, Pages: 1-14 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2023.107317 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.lungcan.2023.107317 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0169500223008553 
|
| Verfasserangaben: | Huriye Seker-Cin, Timothy Kwang Yong Tay, Daniel Kazdal, Klaus Kluck, Markus Ball, Olaf Neumann, Hauke Winter, Felix Herth, Claus-Peter Heußel, Rajkumar Savai, Peter Schirmacher, Michael Thomas, Jan Budczies, Michael Allgäuer, Petros Christopoulos, Albrecht Stenzinger, Anna-Lena Volckmar |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1871920973 | ||
| 003 | DE-627 | ||
| 005 | 20240331080351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231205s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2023.107317 |2 doi | |
| 035 | |a (DE-627)1871920973 | ||
| 035 | |a (DE-599)KXP1871920973 | ||
| 035 | |a (OCoLC)1425209039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Şeker-Cin, Huriye |e VerfasserIn |0 (DE-588)1083854712 |0 (DE-627)848056949 |0 (DE-576)455756902 |4 aut | |
| 245 | 1 | 0 | |a Analysis of rare fusions in NSCLC |b genomic architecture and clinical implications |c Huriye Seker-Cin, Timothy Kwang Yong Tay, Daniel Kazdal, Klaus Kluck, Markus Ball, Olaf Neumann, Hauke Winter, Felix Herth, Claus-Peter Heußel, Rajkumar Savai, Peter Schirmacher, Michael Thomas, Jan Budczies, Michael Allgäuer, Petros Christopoulos, Albrecht Stenzinger, Anna-Lena Volckmar |
| 264 | 1 | |c October 2023 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 27. Juli 2023, Artikelversion: 14. August 2023 | ||
| 500 | |a Gesehen am 05.12.2023 | ||
| 520 | |a Objectives - Molecular diagnosis for targeted therapies has been improved significantly in non-small-cell lung cancer (NSCLC) patients in recent years. Here we report on the prevalence of rare fusions in NSCLC and dissect their genomic architecture and potential clinical implications. - Materials and Methods - Overall, n = 5554 NSCLC patients underwent next-generation sequencing (NGS) for combined detection of oncogenic mutations and fusions either at primary diagnosis (n = 5246) or after therapy resistance (n = 308). Panels of different sizes were employed with closed amplicon-based, or open assays, i.e. anchored multiplex PCR (AMP) and hybrid capture-based, for detection of translocations, including “rare” fusions, defined as those beyond ALK, ROS1, RET and <0.5 % frequency in NSCLC. - Results - Rare fusions involving EGFR, MET, HER2, BRAF and other potentially actionable oncogenes were detected in 0.5% (n = 26) of therapy-naive and 2% (n = 6) TKI-treated tumors. Detection was increased using open assays and/or larger panels, especially those covering >25 genes, by approximately 1-2% (p = 0.001 for both). Patient characteristics (age, gender, smoking, TP53 co-mutations (56%), or mean tumor mutational burden (TMB) (4.8 mut/Mb)) showed no association with presence of rare fusions. Non-functional alterations, i.e. out-of-frame or lacking kinase domains, comprised one-third of detected rare fusions and were significantly associated with simultaneous presence of classical oncogenic drivers, e.g. EGFR or KRAS mutations (p < 0.001), or use of larger panels (frequency of non-functional among the detected rare fusions 57% for 25+ gene- vs. 12% for smaller panels, p < 0.001). As many rare fusions were identified before availability of targeted therapy, mean survival for therapy-naïve patients was 23.8 months, comparable with wild-type tumors. - Conclusion - Approximately 1-2% of advanced NSCLC harbor rare fusions, which are potentially actionable and may support diagnosis. Routine adoption of broad NGS assays capable to identify exact fusion points and potentially retained protein domains can increase the yield of therapeutically relevant molecular information in advanced NSCLC. | ||
| 650 | 4 | |a NGS | |
| 650 | 4 | |a Oncogenic fusion | |
| 650 | 4 | |a Receptor tyrosine kinase | |
| 650 | 4 | |a Targeted therapy | |
| 700 | 1 | |a Tay, Timothy Kwang Yong |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kazdal, Daniel |d 1983- |e VerfasserIn |0 (DE-588)114929650X |0 (DE-627)1009614088 |0 (DE-576)496635867 |4 aut | |
| 700 | 1 | |a Kluck, Klaus |e VerfasserIn |0 (DE-588)122679940X |0 (DE-627)1747876127 |4 aut | |
| 700 | 1 | |a Ball, Markus |e VerfasserIn |0 (DE-588)1057908746 |0 (DE-627)795401108 |0 (DE-576)41391738X |4 aut | |
| 700 | 1 | |a Neumann, Olaf |e VerfasserIn |0 (DE-588)1033375632 |0 (DE-627)741119498 |0 (DE-576)380962381 |4 aut | |
| 700 | 1 | |a Winter, Hauke |e VerfasserIn |0 (DE-588)1162076038 |0 (DE-627)1025509773 |0 (DE-576)176791531 |4 aut | |
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 700 | 1 | |a Heußel, Claus Peter |e VerfasserIn |0 (DE-588)1048631389 |0 (DE-627)780769422 |0 (DE-576)40288146X |4 aut | |
| 700 | 1 | |a Savai, Rajkumar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schirmacher, Peter |d 1961- |e VerfasserIn |0 (DE-588)1020440112 |0 (DE-627)691221197 |0 (DE-576)360427448 |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 700 | 1 | |a Budczies, Jan |d 1970- |e VerfasserIn |0 (DE-588)124086403 |0 (DE-627)706532724 |0 (DE-576)186167679 |4 aut | |
| 700 | 1 | |a Allgäuer, Michael |e VerfasserIn |0 (DE-588)1178366790 |0 (DE-627)1049312597 |0 (DE-576)517751453 |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Volckmar, Anna-Lena |d 1984- |e VerfasserIn |0 (DE-588)173874916 |0 (DE-627)698776666 |0 (DE-576)134713478 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 184(2023) vom: Okt., Artikel-ID 107317, Seite 1-14 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a Analysis of rare fusions in NSCLC genomic architecture and clinical implications |
| 773 | 1 | 8 | |g volume:184 |g year:2023 |g month:10 |g elocationid:107317 |g pages:1-14 |g extent:14 |a Analysis of rare fusions in NSCLC genomic architecture and clinical implications |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2023.107317 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0169500223008553 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231205 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 173874916 |a Volckmar, Anna-Lena |m 173874916:Volckmar, Anna-Lena |d 910000 |d 912000 |e 910000PV173874916 |e 912000PV173874916 |k 0/910000/ |k 1/910000/912000/ |p 17 |y j | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 16 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |e 50000PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 15 | ||
| 998 | |g 1178366790 |a Allgäuer, Michael |m 1178366790:Allgäuer, Michael |d 910000 |d 912000 |e 910000PA1178366790 |e 912000PA1178366790 |k 0/910000/ |k 1/910000/912000/ |p 14 | ||
| 998 | |g 124086403 |a Budczies, Jan |m 124086403:Budczies, Jan |d 910000 |d 912000 |e 910000PB124086403 |e 912000PB124086403 |k 0/910000/ |k 1/910000/912000/ |p 13 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |e 50000PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 12 | ||
| 998 | |g 1020440112 |a Schirmacher, Peter |m 1020440112:Schirmacher, Peter |d 910000 |d 912000 |e 910000PS1020440112 |e 912000PS1020440112 |k 0/910000/ |k 1/910000/912000/ |p 11 | ||
| 998 | |g 1048631389 |a Heußel, Claus Peter |m 1048631389:Heußel, Claus Peter |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1048631389 |e 950000PH1048631389 |e 950900PH1048631389 |e 50000PH1048631389 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 9 | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1016095236 |e 950000PH1016095236 |e 950900PH1016095236 |e 50000PH1016095236 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 8 | ||
| 998 | |g 1162076038 |a Winter, Hauke |m 1162076038:Winter, Hauke |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PW1162076038 |e 950000PW1162076038 |e 950900PW1162076038 |e 50000PW1162076038 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 7 | ||
| 998 | |g 1033375632 |a Neumann, Olaf |m 1033375632:Neumann, Olaf |d 910000 |d 912000 |e 910000PN1033375632 |e 912000PN1033375632 |k 0/910000/ |k 1/910000/912000/ |p 6 | ||
| 998 | |g 1057908746 |a Ball, Markus |m 1057908746:Ball, Markus |d 910000 |d 912000 |e 910000PB1057908746 |e 912000PB1057908746 |k 0/910000/ |k 1/910000/912000/ |p 5 | ||
| 998 | |g 122679940X |a Kluck, Klaus |m 122679940X:Kluck, Klaus |d 910000 |d 912000 |e 910000PK122679940X |e 912000PK122679940X |k 0/910000/ |k 1/910000/912000/ |p 4 | ||
| 998 | |g 114929650X |a Kazdal, Daniel |m 114929650X:Kazdal, Daniel |d 910000 |d 912000 |e 910000PK114929650X |e 912000PK114929650X |k 0/910000/ |k 1/910000/912000/ |p 3 | ||
| 998 | |g 1083854712 |a Şeker-Cin, Huriye |m 1083854712:Şeker-Cin, Huriye |d 910000 |d 912000 |e 910000PS1083854712 |e 912000PS1083854712 |k 0/910000/ |k 1/910000/912000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1871920973 |e 4425365453 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Huriye Seker-Cin, Timothy Kwang Yong Tay, Daniel Kazdal, Klaus Kluck, Markus Ball, Olaf Neumann, Hauke Winter, Felix Herth, Claus-Peter Heußel, Rajkumar Savai, Peter Schirmacher, Michael Thomas, Jan Budczies, Michael Allgäuer, Petros Christopoulos, Albrecht Stenzinger, Anna-Lena Volckmar"]},"id":{"doi":["10.1016/j.lungcan.2023.107317"],"eki":["1871920973"]},"physDesc":[{"extent":"14 S."}],"recId":"1871920973","origin":[{"dateIssuedDisp":"October 2023","dateIssuedKey":"2023"}],"person":[{"family":"Şeker-Cin","role":"aut","given":"Huriye","display":"Şeker-Cin, Huriye"},{"display":"Tay, Timothy Kwang Yong","role":"aut","given":"Timothy Kwang Yong","family":"Tay"},{"display":"Kazdal, Daniel","given":"Daniel","role":"aut","family":"Kazdal"},{"display":"Kluck, Klaus","family":"Kluck","role":"aut","given":"Klaus"},{"display":"Ball, Markus","family":"Ball","given":"Markus","role":"aut"},{"family":"Neumann","role":"aut","given":"Olaf","display":"Neumann, Olaf"},{"role":"aut","given":"Hauke","family":"Winter","display":"Winter, Hauke"},{"display":"Herth, Felix","family":"Herth","role":"aut","given":"Felix"},{"display":"Heußel, Claus Peter","role":"aut","given":"Claus Peter","family":"Heußel"},{"family":"Savai","given":"Rajkumar","role":"aut","display":"Savai, Rajkumar"},{"display":"Schirmacher, Peter","given":"Peter","role":"aut","family":"Schirmacher"},{"display":"Thomas, Michael","role":"aut","given":"Michael","family":"Thomas"},{"given":"Jan","role":"aut","family":"Budczies","display":"Budczies, Jan"},{"role":"aut","given":"Michael","family":"Allgäuer","display":"Allgäuer, Michael"},{"display":"Christopoulos, Petros","family":"Christopoulos","given":"Petros","role":"aut"},{"role":"aut","given":"Albrecht","family":"Stenzinger","display":"Stenzinger, Albrecht"},{"role":"aut","given":"Anna-Lena","family":"Volckmar","display":"Volckmar, Anna-Lena"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"320649733","disp":"Analysis of rare fusions in NSCLC genomic architecture and clinical implicationsLung cancer","pubHistory":["1.1985 -"],"origin":[{"publisher":"Elsevier","dateIssuedKey":"1985","dateIssuedDisp":"1985-","publisherPlace":"Amsterdam [u.a.]"}],"note":["Gesehen am 20.02.20"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"title":[{"title_sort":"Lung cancer","title":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer"}],"part":{"extent":"14","text":"184(2023) vom: Okt., Artikel-ID 107317, Seite 1-14","volume":"184","year":"2023","pages":"1-14"},"id":{"zdb":["2025812-4"],"issn":["1872-8332"],"eki":["320649733"]}}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"note":["Online verfügbar: 27. Juli 2023, Artikelversion: 14. August 2023","Gesehen am 05.12.2023"],"title":[{"subtitle":"genomic architecture and clinical implications","title":"Analysis of rare fusions in NSCLC","title_sort":"Analysis of rare fusions in NSCLC"}]} | ||
| SRT | |a SEKERCINHUANALYSISOF2023 | ||